Cite
Mo1219 EPIGENETICALLY REGULATED GENE ENHANCERS AS NOVEL RATIONAL THERAPEUTIC TARGETS TO IMPEDE COLORECTAL CANCER PROGRESSION.
MLA
Shao, Xinxin, et al. “Mo1219 EPIGENETICALLY REGULATED GENE ENHANCERS AS NOVEL RATIONAL THERAPEUTIC TARGETS TO IMPEDE COLORECTAL CANCER PROGRESSION.” Gastroenterology (00165085), vol. 166, no. 5, May 2024, p. S-983. EBSCOhost, https://doi.org/10.1016/S0016-5085(24)02738-0.
APA
Shao, X., Finnegan, E., Caragine, C., Maguire, S. L., Van Minsel, P., Kirwan, G., Thienpont, B., Genua, F., Sanjana, N., & Das, S. (2024). Mo1219 EPIGENETICALLY REGULATED GENE ENHANCERS AS NOVEL RATIONAL THERAPEUTIC TARGETS TO IMPEDE COLORECTAL CANCER PROGRESSION. Gastroenterology (00165085), 166(5), S-983. https://doi.org/10.1016/S0016-5085(24)02738-0
Chicago
Shao, Xinxin, Ellen Finnegan, Christina Caragine, Sarah L. Maguire, Paulien Van Minsel, Gráinne Kirwan, Bernard Thienpont, Flavia Genua, Neville Sanjana, and Sudipto Das. 2024. “Mo1219 EPIGENETICALLY REGULATED GENE ENHANCERS AS NOVEL RATIONAL THERAPEUTIC TARGETS TO IMPEDE COLORECTAL CANCER PROGRESSION.” Gastroenterology (00165085) 166 (5): S-983. doi:10.1016/S0016-5085(24)02738-0.